top of page
scientific-chemistry-glassware-for-research-in-lab-2021-09-03-13-36-50-utc.jpg

ACESION PHARMA

A Danish biotech aiming to develop more efficacious & safer drugs for the treatment of atrial fibrillation

ABOUT
ACESION

Acesion Pharma ApS is a Danish biotech company founded in 2011 as a spin out from the company Neurosearch and University of Copenhagen. By inhibiting the SK ion channel, we aim to develop first-in-class drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia.

biotechnology-research-scientist-viewing-specimen-2022-03-08-00-59-52-utc.jpg
grey-bg.jpg

About Atrial Fibrillation

Atrial fibrillation (AF) is the most common type of cardiac arrhythmia, estimated to affect 25 million people in the EU and US in 2030.

grey-bg.jpg
dims.jpeg

Latest News

bottom of page